LIGAND PHARMACEUTICALS INC 4
4 · Pelthos Therapeutics Inc. · Filed Nov 10, 2025
Insider Transaction Report
Form 4
LIGAND PHARMACEUTICALS INC
10% Owner
Transactions
- Award
Senior Secured Convertible Note
2025-11-06$9000000.00/shExercise: $34.44→ Common Stock (261,309 underlying)
Footnotes (1)
- [F1]On November 6, 2025, Pelthos Therapeutics Inc. (the "Issuer") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the "Convertible Note") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person.